- Home
- FDMM vs PALI Comparison
FDMM vs PALI Comparison
Compare FDMM & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
SELL
Current Price
$1.49
Company Overview
Basic Information| Metric | FDMM | PALI |
|---|---|---|
| Founded | 2026 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 369.3M | 359.0M |
| IPO Year | 2026 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FDMM | PALI |
|---|---|---|
| Price | $9.81 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.80 |
| AVG Volume (30 Days) | 20.3K | ★ 3.3M |
| Earning Date | N/A | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $9.80 | $1.32 |
| 52 Week High | $9.88 | $9.50 |
Technical Indicators
Market Signals| Indicator | FDMM | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 42.48 |
| Support Level | $9.80 | $1.50 |
| Resistance Level | $9.86 | $2.18 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 59.68 |
Price Performance
Historical Comparison FDMM
PALI
About FDMM Freedom Metals Acquisition Corp. Class A Ordinary Shares
Freedom Metals Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.